Physician profile

Mark A Woods

Family Medicine · Ozark, MO

NPI 1558451435

$4,183.27

in general payments reported to CMS, 2019-2025

31 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Allergan, INC. $424.77 2019-2020
Daiichi Sankyo INC. $391.27 2019-2020
Pfizer INC. $379.28 2019-2020
Astrazeneca Pharmaceuticals LP $366.64 2019-2020
Glaxosmithkline, LLC. $257.68 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $237.24 2019-2020
Lilly USA, LLC $235.58 2019-2020
Novo Nordisk INC $226.31 2019-2020
Amgen INC. $213.96 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $192.51 2019-2020
Merck Sharp & Dohme LLC $183.67 2019-2020
Amarin Pharma, INC. $159.79 2019
Sanofi-Aventis U.S. LLC $140.01 2019
Radius Health, INC. $109.79 2019-2020
Abbvie INC. $98.97 2019-2020
Show all 31 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark A Woods

$4,183.27

in general payments reported 2019-2025

Years
2019-2020
Top company
Allergan, INC.

https://glasscript.com/doctor/342407/mark-a-woods

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.